PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35387819-3	2022	This trial will investigate the impact of nelfinavir, a protease inhibitor that targets the protein kinase B (AKT) pathway on disease-free survival (DFS).	Nelfinavir	42-52	protein tyrosine kinase 2 beta	Homo sapiens	92-108